新鋭醫藥(06108.HK)擬4400萬元出售賽科國際醫療集團的25%股權
格隆匯3月29日丨新鋭醫藥(06108.HK)宣佈,於2022年3月29日,公司全資附屬Major Bright Holdings Limited擬以人民幣4400萬元出售目標公司賽科國際醫療集團有限公司的25%股權。目標集團主要從事於中國買賣醫療器械、醫療設備及醫療消耗品。
公吿稱,董事一直有不時審視集團的業務,藉此提升集團的競爭力及增強財務狀況。集團將專注於大有前景的中成藥市場及銷售表現,尋覓收購新分銷權的新機會,並探索新併購機會,為集團及全體股東締造更高回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.